Articles tagged with Cancer Treatments
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
Researchers at Northwestern University have developed a new CRISPR delivery system that triples efficiency using DNA-wrapped nanoparticles, improving safety and effectiveness. The new system, called LNP-SNAs, targets specific cells and tissues, reducing toxicity and boosting gene-editing efficiency by threefold.
A study reveals significant global disparities in cancer research funding, with lower-income countries struggling to keep pace. Cancer surgery and radiotherapy research are particularly underfunded, urging a strong case for increased investment.
Human cells use a synchronized traffic control system to monitor nutrient levels and precisely control cellular energy balance, blood sugar levels, and energy management. This finding offers promising new targets for treating diabetes and cancer.
Researchers found that specific nutrient supplements like amino acids, probiotics, and herbs like ginger can effectively reduce nausea, vomiting, and diarrhea. Dietary counseling also showed promise in reducing common GI side effects. Oral nutritional supplements, however, did not demonstrate benefits in easing symptoms.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
Researchers identified a core group of 15 bacterial genera in 6 types of GI tumors that predicts prognosis. Microbiome signals inside tumors carry prognostic and therapeutic information that can be measured on routine tissue. The study suggests a microbiota-based risk score to identify high-risk patients and inform treatment decisions.
A new UCLA-led study finds that government housing assistance reduces the risk of medical bill stress by nearly seven percentage points among US renters with cancer, leading to improved quality of life and reduced poor physical and mental health outcomes.
The EASYGEN consortium will develop a fully automated platform for manufacturing personalized cell therapies within days, accelerating patient access and reducing costs. EBMT is participating in the study examining current CAR-T treatment processes and contributing to patient education and advocacy efforts.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Researchers evaluated clinical outcomes of endoscopic resection in sellar chondrosarcomas, revealing common symptoms like blurring of vision and headaches. The study also provides recommendations for accurate diagnosis using imaging data and clinical features.
University of Arizona researchers develop a new formulation of paclitaxel, called Paclitaxome, which improves delivery to tumor sites and reduces side effects. The modified drug combination outperforms existing chemotherapy treatments in tests against triple-negative breast cancer and advanced pancreatic cancer in mice.
Researchers at The Mount Sinai Hospital successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma. They identified a combination of compounds approved by the FDA that effectively targeted the lymphoma, with one compound, anti-CCR4, showing particular promise.
A new 'dual-mode' tracer agent shows promise in helping surgeons image and plan prostate cancer procedures while also providing guided surgery with real-time radiation detection. The tracer targets PSMA, a protein highly expressed on prostate cancer cells, offering high-resolution visual guidance and targeted radiation density detection.
Researchers at Mount Sinai Hospital discovered that adding everolimus to standard chemotherapy improves outcomes for patients with advanced triple-negative breast cancer. The combination therapy reduces the risk of disease progression or death by 52%.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
Researchers successfully treat mouse tumor with radioactive carbon ion beam, achieving complete control without major neurological side effects. The BARB project advances image-guided particle therapy using exotic beams, showing feasibility and effectiveness.
Researchers found that combining aramchol with regorafenib killed liver and colorectal cancer cells more effectively than either drug alone, triggering stress responses and disrupting survival pathways. The combination was especially effective in cells with a genetic variant called ATG16L1 T300.
The seminar, part of a DAAD-JSPS collaboration, will cover the latest topics on drug design and treatment protocols for photodynamic therapy. Researchers from Japan and Germany will present their recent research results on PDT, including nano-DDS applications.
A study at the Garvan Institute of Medical Research found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment. The JNK pathway acts as a cellular alarm system, and its disruption leads to treatment resistance.
Researchers at Peking Union Medical College Hospital have developed bi-functional molecules combining PD-1 blockade with precision IL-2 delivery to revive 'sleepy' T cells. This combination enhances immune cell response, reducing toxicity and improving cancer treatment outcomes.
The FDA-approved MI Cancer Seek test is a comprehensive molecular profiling assay that delivers accurate and reliable results from minimal tissue input. It identifies key biomarkers linked to FDA-approved treatments for several major cancers, including breast, lung, colon, melanoma, and endometrial cancers.
The ARCHER study aims to determine whether ultra-hypofractionated stereotactic body radiation therapy is non-inferior to hypofractionated radiotherapy in preserving bladder function. Patients will be randomly assigned to receive either 4 weeks of daily or 5 days of ultra-hypofractionated SBRT.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Weill Cornell Medicine researchers Dr. Anna Nam and Dr. Maria Cecilia Lira have been awarded prestigious Pew fellowships to support their innovative cancer and biomedical science research. Dr. Nam is investigating the genetic determinants of Hodgkin lymphoma, while Dr. Lira aims to develop novel therapies for brain tumors.
The Huntsman Cancer Institute is launching new clinical trials to explore how theranostics can help more patients. Theranostics combines diagnostics and therapeutics to deliver targeted radiation directly to cancer cells, offering a powerful approach to finding and treating cancer.
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer. The treatment was well-tolerated and showed improved outcomes compared to standard treatments.
A new study from the University of Missouri-Columbia highlights the importance of consistent primary care coordination in cancer survivorship care. The research found that only a third of patients consistently saw the same primary care clinician during and after cancer treatment, leading to fragmented care and gaps in patient services.
Researchers identify three tumor-reactive T cell subpopulations that exhibit selective expansion in ovarian cancer patients. CD8+ TCF7-expressing Tpex cells demonstrate self-renewal capacity and generate stem-like progenies, which may enhance persistence and specificity in current TIL therapy.
The Pew Charitable Trusts has announced the 2025 class of the Pew-Stewart Scholars Program for Cancer Research, supporting five early-career scientists in innovative research projects. The recipients will explore pressing topics such as complex cancer mechanisms and new drug targets.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
A new web-based tool has been developed to provide tailored resources for states and local leaders to reduce lung cancer mortality rates. The tool addresses health equity and incorporates user feedback to offer recommendations based on regional needs.
Researchers discovered that disrupted brain-liver communication due to vagus nerve dysregulation leads to damage in liver metabolism and cachexia development. Targeted blocking of the right vagus nerve prevents cachexia's development, enhances chemotherapy response, and improves overall health and survival in mice.
The Lancet commission emphasizes the need for concrete goals to reduce hepatocellular carcinoma's growing disease burden. The authors propose a 2% annual reduction in age-standardized incidence rates and recommend evidence-based strategies to tackle viral hepatitis, alcohol consumption, environmental risk factors, and disparities in he...
Researchers developed pH-responsive graphene-based nanocarriers that can target cancer cells, achieving efficient and safe drug delivery. The material's surface charge adapted to the acidic tumor environment, allowing it to bind and enter cancer cells while avoiding healthy tissues.
A study published in JCO Precision Oncology found that genetic testing can significantly improve patient safety by providing tailored doses of chemotherapy, reducing severe side effects. The test identifies variants in two genes that impact how the body processes chemotherapy drugs, allowing doctors to adjust doses and minimize harm.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
A new study in The American Journal of Pathology reveals that perilipin 2 protein modulates aggressive cancer progression in advanced lung adenocarcinoma by regulating lipid droplet accumulation. High perilipin 2 expression is associated with more aggressive disease progression and shorter recurrence-free survival times.
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
Researchers found that decompression with a nasogastric tube is linked to reduced complications in patients after oesophageal cancer surgery. This challenges declining trend of abandoning the tube post-surgery, which was previously thought to be safe.
A CCNY research team found chemotherapy disrupts gene regulation in brain regions linked to decision-making and executive function. This may explain long-term cognitive issues experienced by some cancer patients after treatment.
Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A recent study identified four genes associated with treatment resistance to immunotherapy in melanoma patients. The genes, CD24, NFIL3, FN1, and KLRK1, were found to be linked to mechanisms of immune evasion and suppression of the inflammatory response. Patients with high expression of these genes had significantly lower overall survi...
Lydia Kavraki, a pioneering researcher in robotics and AI, has been elected to the European Academy of Sciences. Her work on physical AI, transforming robotics and biomedicine, and leadership at Rice University's Ken Kennedy Institute have earned her this prestigious honor.
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
Researchers propose a synergistic combination strategy using systemic type I interferons (IFN-I) and local TLR7/8 agonists to enhance dendritic cell activation and inhibit metastatic tumors. This approach enhances early innate immune control and later induces CD8+ T cell responses.
Researchers discovered a compound, EPS3.9, produced by deep-sea bacteria that triggers pyroptosis to inhibit tumor growth and exhibit potent anti-cancer effects. The study highlights the importance of exploring marine microbial resources for developing new drugs.
Researchers have identified CDX1 and CDX2 as key molecules that counteract β-catenin and suppress stemness in colon cancer. Deletion or overexpression of these proteins increased tumor aggressiveness and expression of cancer stemness-related genes, suggesting a potential therapeutic target.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
Researchers at the University of Ottawa have made a breakthrough in developing nanoparticles that not only deliver drugs but also contribute to treatment. Their proof-of-concept study shows that particles can be armed with therapeutic potential, revolutionizing the field of nanomedicine.
The University Hospitals Seidman Cancer Center has become the first in the US to implement Akesis' Galaxy RTI device, advancing Stereotactic Radiosurgery (SRS) with enhanced precision and treatment efficiency. The center will also serve as a research hub for this innovative technology.
A recent study identified 37 human-specific genes linked to brain development and cognitive abilities, which are hijacked by cancer to drive tumor growth. The researchers discovered nearly half of these genes become aberrantly activated in cancerous tissues, promoting tumor cell proliferation.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
Researchers at the University of Pennsylvania designed a new recipe for mRNA vaccines by adding phenol groups, which reduce inflammation and improve vaccine effectiveness. The modified lipids improved vaccine performance in various diseases, including COVID-19, cancer, and genetic diseases, with enhanced efficacy and reduced side effects.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
Researchers have discovered a key role of centrosomes in signaling cells to proliferate despite DNA damage, enabling cancer resistance. The study suggests targeting Polo-like kinase 1 could prevent adaptation to therapy-induced DNA damage and drug resistance.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.